Age and Frailty Should Be Considered Independently When Evaluating Potential Risk for Side Effects Among Older Adults Treated with ICIs
Findings from a population-level retrospective cohort study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma
Evidence for efficacy is based on the results from the ELARA study
EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in Paediatric Patients
The risk of ocular toxicity, including risk of severe visual loss and need for monitoring in paediatric patients treated with crizotinib
An Updated Overview of Estimates for Cancer Incidence and Mortality in the Latin America and the Caribbean Region
Data for 32 countries in this region reflect important underlying sociodemographic changes
Risk of Anal Cancer Significantly Lower with Treatment for Anal High-Grade Squamous Intraepithelial Lesions
Findings from a phase III ANCHOR study
Efficacy and Safety of Trastuzumab and Pertuzumab in Combination with FLOT for Perioperative Treatment of Resectable, HER2-positive Oesophagogastric Adenocarcinoma
Improved pathologic complete response and nodal negativity rates, but higher rates of diarrhoea and leukopenia observed
A Clinical Signal of Efficacy Observed with a Combination of Nivolumab and Ipilimumab Over Platinum Doublet in Fit Elderly Patients with Advanced NSCLC
Findings from the Energy-GFPC 06-2015 study
Carriers of a Germline Pathogenic Variant in CDKN2A are at a High Lifetime Risk of Pancreatic Ductal Adenocarcinoma
Surveillance in this population leads to diagnosis of early-stage disease in one third of patients resulting in increased resectability and a substantial 5-year survival rate
EMA Recommends Extension of Therapeutic Indications for Selinexor
New indication concerns a combination of selinexor with bortezomib and dexamethasone for the treatment of multiple myeloma
No Survival Benefit for Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Patients with ER-positive/HER2-negative Breast Cancer with High Genomic Grade Index
Final results of the Unicancer ASTER 70s study
Longest Follow-Up of CAR T-Cell Therapy in Mantle Cell Lymphoma Points Out to Long-Term Responses with Manageable Safety in Patients with Relapsed/Refractory Disease
Findings from a pivotal ZUMA-2 study support the investigation of CAR T-cell therapy in earlier lines of treatment
FDA Approves Ivosidenib in Combination with Azacitidine for Newly Diagnosed AML
It is approved for use in the older or patients with comorbidities who have acute myeloid leukaemia with a susceptible IDH1 mutation detected by an FDA-approved test